| Sample / Model | Evidence (CASP1 / NLRP3 / IL-1β / IL-18 / …) |
|---|---|
| plasma |
(Anderson, 2021 #1266, MSD assay) high NLRP3 (ie >90th percentile, 16.2+ ng/mL) more common in PD: 17.7 vs 10.3% (or, if NSAID users are excluded 22.5 vs 10.1%) Severity와 correlation 되는 셋중둘 증거 (Fan, 2020 #657) Plasma, PD (N=43), MSD, fig3] ↑ IL-1β correlates with H&Y (r=0.4), UPDRSIII (r=0.3), aSyn (r=0.6, fig5) (cf, UPDRS I과는 no correlation) |
| plasma | (Wang, 2020 #1638) 40 sPD ↑ IL-1β |
| serum |
(Chatterjee, 2020 #1263) ↑ NLRP3 (ELISA) PD (33.56 ± 5.05 ng/ml) vs controls (6.97 ± 1.44 ng/ml), huge effect size!!! But no difference between H&y 1 vs 2/3 (Chatterjee, 2020 #1263) n=27, ↑ IL-1β (ELISA) (219.83 ± 58.59 pg/ml) vs (45.53 ± 15.06 pg/ml) But no difference between H&y 1 vs 2/3 (Zhang, 2016 #583) n=8, IL-1β (slight ↑ but no significance) (Cheng, 2020 #1645) ↑ MIF (macrophage migration inhibitory factor (glycosylation-inhibiting factor)) |
| Serum |
(Zhou, 2016 #584)(fig3) ↑ caspase-1 activity (근데 자세히 보니 ELISA 사용했으니 ACTIVITY 아니네) (Zhou, 2016 #584)(fig3) ↑ IL-1β |
| Serum |
(Gordon, 2018 #585) ↑ circulating caspase-1 (ELISA) in a cohort of 21 PD patients (p = 0.023; fig. S1C) Severity와 correlation 되는 셋중셋 증거 Inhouse, RNA-Seq: of IL-1β serum levels with motor severity & progression; PPMI (p=6.02e-6) & PDBP (p=0.0034), but with very week |
| Serum | (Hu, 2015 #1794) ↑ IL-1β [median(quartile)] (pg/ml) control (n=31) 8.215 (7.265~9.432), NPRBD (n=102, 대개 early): 34.262 (9.527~53.584) PBRD (n=40, 대개 early): 41.578 (9.528~128.980), PD에서 (variable하지만) control 과 differentiation 되네. 하지만 this is negated by AMP-PD data |
| Serum |
(Blum-Degena, 1995 #653) in PD (n=22), ↑ IL-1β in CSF & plasma (Pirttila, 1994 #1796) = IL1b |
| Serum (new) | (Karpenko, 2018 #1902) 차이꽤 |
| blood | (Miliukhina, 2020 #1903) min-max 이니 ma 불가 |
| Serum | (Kim, 2018 #1905) IL-1b and IL-2 were undetectable (MA제외) in 68% (PD group: 71% vs. control group: 60%; LLOD: 0.03 g/ml) and 35% (PD group: 28% vs. control group: 55%; LLOD: 0.10 pg/ml) of the serum samples, respectively. |
| PBMC |
(Fan, 2020 #657) PD (N=43), PBMC, WB] ↑ (X2) NLRP3 mRNA & protein, ↑ ASC mRNA, caspase-1 mRNA & protein, (Fan, 2020 #657) PD (N=43), PBMC] PBMC cell pellet lysate (no culture), WB, ↑ IL-1β & (Reale 2009) PD (N=40), PBMC culture supernatant, ↑ IL-1β (mRNA and protein, ELISA, 50.8 vs 73.7, correlate with UPDRSIII (r=0.36) and H&Y staging. Carta MJF PDRx20230531 (PBMC culture, ELISA): ↑ IL-1β, ↑ IL-18 |
| NDE in PLASma (L1CAM) |
(Anderson, 2021 #1266, IMMunoblotting) ↑ nlrp3, ASC, CASP1, and GSDMD, and Pro-IL-1B (Fig. 3, all 큰 차이로, There was clearly a higher proportion of PD patients with detectable EV-borne NLRP3 [EVs: n = 31 (31% of PD)] compared with controls [EVs: n = 11 (18% of controls)] (P = 0.11), FIG3: nde-NLRP3, ASC, pro-ILb, clea |
| limitation | (Anderson, 2021 #1560) numerous cell types including microglia and MNC have the potential to contribute to an extracellular pool of pyroptosis-related proteins (Supplemental Figs. 2 and 3). |
| MPTP | (Zhang, 2016 #583) MPTP-Mice: ↑ IL-1b mRNA in SN |
| MPTP |
(Zhou, 2016 #584)(fig3) ↑ caspase-1 (Zhou, 2016 #584)(fig3) ↑ IL-1b (midbrain) |
| 6-ohda | Gordon, 2018 #585) fig s2) ↑ NLRP3 (mRNA & protiein), ↑ ASC (mRNA), ↑ ASC protein (fig1h), ↑ caspase-1 (mRNA), ↑ pro-caspase1 & cleaved-caspase 1 (protein) |
| LPS (Mice) |
(Arioz, 2019 #1934) LPS(ip, 5mpk)→ ↑ IBA1 (x1.1, IF, FIG3C), ↑ # of mg cells (x1.5, IF, FIG3e) (Arioz, 2019 #1934) LPS(ip, hippocampus) ↑ (~X1.7) (110kDa) NLRP3 (wb, fig2D), ↑ (~X6) NLRP3 (IF, fig3b) ↑ (~X2) ASC (wb, fig2e) (Arioz, 2019 #1934) LPS(ip, 5mpk)→ ↑ (~X10) il-1B (wb, fig2c) |
| Mitopark | Gordon, 2018 #585) FIG S3) ↑ NLRP3 (in SN, mRNA & PROTein), fig 1i) ↑ ASC, ↑ cleaved caspase-1, |
| ASyn TG | (Zhang, 2016 #583) aSyn TG-Mice: ↑ IL-1b mRNA in SN |
| ASyn TG |
(Zhou, 2016 #584)(fig3) ↑ caspase-1 (Zhou, 2016 #584)(fig3) ↑ IL-1b (midbrain) |
| ASyn PFF |
Gordon, 2018 #585) figs4) ↑ colocalization of NLRP3 in microglia (cf no colocalization in TH+ cells), fig 1k,l) ↑ ASC, ↑ cleaved caspase-1 Cf in vitro, microglia) Gordon, 2018 #585) fibrillar aSyn → ↑ NLRP3, ↑ ASC, ↑ cleaved caspase-1 (fig 2) |
| human iPSC-derived microglia (from normal fibroblast) |
(Trudler, 2021 #1900) fig 2d, : oligomerci (not monomeric) aSyn → caspase 1 (Trudler, 2021 #1900) fig 2c, : oligomerci (not monomeric) aSyn → IL-1b |
Correction
| Sample / Model | Evidence |
|---|---|
| human iPSC-derived microglia | Inhouse, ] MCC950 → ↓ ASC, ↓ p20 caspase (NLRP3에 대해서는 Tx가 억제만 하는거지 양을 줄이는 게 아니니 볼 필요 없겠구나) |
| human primary microglia] |
Inhouse, human primary microglia] MCC950 & Inzomelid → ↓ IL-1b TR06673219 → ↓ IL-1b |
| human primary microglia | (Wang, 2016 #639) NLRP3 inflammasome activation in a neuronal cell line → Caspase-1 directly cleave α-syn at Asp121 → this cleaved form was more prone to aggregation |
Uncertain Spans
| location | transcription | uncertainty |
|---|---|---|
| Anderson 2021 plasma row | >90th percentile, 16.2+ ng/mL | Decimal/footnote markers around 90th are partly faded; superscript ordinal could read differently. |
| Karpenko row | 차이꽤 | Trailing Korean fragment is small; full word may be 차이 꽤 큼 or similar but only 차이꽤 is legible on this capture. |
| Anderson NDE row | Fig. 3, all 큰 차이로, | The Korean fragment after all ends mid-clause; sentence likely continues into the next column. |
| Korean note in Serum row | 근데 자세히 보니 ELISA 사용했으니 ACTIVITY 아니네 | Hand-style font; one or two characters could differ but overall reading matches OCR. |
| Inhouse correction row | ↓ p20 caspase | ”p20” could read “p10” or “p20” — superscript and adjacent symbols are small. |